Association of UGT1A16, UGT1A128, or ABCC2 c.3972CT genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis

Effects of UGT1A1*6 and UGT1A1*28 genetic polymorphisms on irinotecan-induced severe toxicities in Asian cancer patients are inconclusive. Also, ABCC2 c.3972C>T may affect toxicity of irinotecan. The aim was to assess the aggregated risk of neutropenia or diarrhea in Asian cancer patients taking...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational science 2022-07, Vol.15 (7), p.1613
Main Authors: Atasilp, Chalirmporn, Biswas, Mohitosh, Jinda, Pimonpan, Nuntharadthanaphong, Nutthan, Rachanakul, Jiratha, Hongkaew, Yaowaluck, Vanwong, Natchaya, Saokaew, Surasak, Sukasem, Chonlaphat
Format: Article
Language:English
Subjects:
Analysis
Cancer
Care and treatment
Diagnosis
Diarrhea
Genetic aspects
Genetic polymorphisms
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Effects of UGT1A1*6 and UGT1A1*28 genetic polymorphisms on irinotecan-induced severe toxicities in Asian cancer patients are inconclusive. Also, ABCC2 c.3972C>T may affect toxicity of irinotecan. The aim was to assess the aggregated risk of neutropenia or diarrhea in Asian cancer patients taking irinotecan and inherited UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic variants. A PubMed literature search for eligible studies was conducted. Odds ratios (ORs) were measured using RevMan software where p values T genetic variant were not significantly associated with neutropenia (OR 1.67; 95% CI 0.98-2.84; p = 0.06) and were significantly associated with a reduction in irinotecan-induced diarrhea (OR 0.31; 95% CI 0.11-0.81; p = 0.02). Asian cancer patients should undergo screening for both UGT1A1*6 and UGT1A1*28 genetic variants to reduce substantially irinotecan-induced severe toxicities.
ISSN:1752-8054
DOI:10.1111/cts.13277